Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors
Public Deposited- Creator
- Combest, A. J.
- Roberts, P. J.
- Dillon, P. M.
- Sandison, K.
- Hanna, S. K.
- Ross, C.
- Habibi, S.
- Zamboni, B.
- Muller, M.
- Brunner, M.
- Sharpless, N. E.
- Zamboni, W. C.
- Abstract
- Rodent studies are a vital step in the development of novel anticancer therapeutics and are used in pharmacokinetic (PK), toxicology, and efficacy studies. Traditionally, anticancer drug development has relied on xenograft implantation of human cancer cell lines in immunocompromised mice for efficacy screening of a candidate compound. The usefulness of xenograft models for efficacy testing, however, has been questioned, whereas genetically engineered mouse models (GEMMs) and orthotopic syngeneic transplants (OSTs) may offer some advantages for efficacy assessment. A critical factor influencing the predictability of rodent tumor models is drug PKs, but a comprehensive comparison of plasma and tumor PK parameters among xenograft models, OSTs, GEMMs, and human patients has not been performed.
- Date of publication
- 2012
- Keyword
- DOI
- Identifier
- Onescience id: c23f21cf8ced81768daf50b2c3b0349fb5e2c1b9
- PMCID: PMC3481896
- Publisher DOI: https://doi.org/10.1634/theoncologist.2012-0274
- PMID: 22993143
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- The Oncologist
- Journal volume
- 17
- Journal issue
- 10
- Language
- English
- ISSN
- 1549-490X
- 2159-8401
- 1083-7159
Relations
- Parents:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
EuropePMC-PMC3481896.pdf | November 1, 2020 | Public | Download |